IL105468A - Pharmaceutical preparations containing agonists for TH5-1-like receptors for rectal administration - Google Patents

Pharmaceutical preparations containing agonists for TH5-1-like receptors for rectal administration

Info

Publication number: IL105468A
Authority: IL; Israel
Prior art keywords: pharmaceutical composition; methyl; active ingredient; pharmaceutically acceptable; indole
Prior art date: 1992-05-07

Application number

IL10546893A

Other languages

English (en)

Hebrew (he)

Other versions

IL105468A0 (en

Original Assignee

Glaxo Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-07

Filing date

1993-04-20

Publication date

1998-09-24

1993-04-20 Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa

1993-08-18 Publication of IL105468A0 publication Critical patent/IL105468A0/xx

1998-09-24 Publication of IL105468A publication Critical patent/IL105468A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
239000000018 receptor agonist Substances 0.000 title claims abstract description 13
229940044601 receptor agonist Drugs 0.000 title claims abstract description 13
239000004480 active ingredient Substances 0.000 claims abstract description 27
239000000203 mixture Substances 0.000 claims abstract description 23
150000001875 compounds Chemical class 0.000 claims abstract description 21
239000012453 solvate Substances 0.000 claims abstract description 14
239000012458 free base Substances 0.000 claims abstract description 13
238000011282 treatment Methods 0.000 claims abstract description 11
208000002193 Pain Diseases 0.000 claims abstract description 4
238000004519 manufacturing process Methods 0.000 claims abstract 2
238000000034 method Methods 0.000 claims abstract 2
239000000829 suppository Substances 0.000 claims description 14
239000002585 base Substances 0.000 claims description 13
208000019695 Migraine disease Diseases 0.000 claims description 11
206010027599 migraine Diseases 0.000 claims description 11
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
229940116364 hard fat Drugs 0.000 claims description 8
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical group CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 8
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
239000007909 solid dosage form Substances 0.000 claims description 5
206010019233 Headaches Diseases 0.000 claims description 4
231100000869 headache Toxicity 0.000 claims description 4
208000006561 Cluster Headache Diseases 0.000 claims description 3
208000008548 Tension-Type Headache Diseases 0.000 claims description 3
208000018912 cluster headache syndrome Diseases 0.000 claims description 3
206010009094 Chronic paroxysmal hemicrania Diseases 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
206010043269 Tension headache Diseases 0.000 claims description 2
ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims description 2
208000007777 paroxysmal Hemicrania Diseases 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
208000019553 vascular disease Diseases 0.000 claims description 2
239000004615 ingredient Substances 0.000 claims 3
239000003937 drug carrier Substances 0.000 abstract description 4
239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
239000003814 drug Substances 0.000 description 6
150000003839 salts Chemical class 0.000 description 5
238000009472 formulation Methods 0.000 description 4
150000002475 indoles Chemical class 0.000 description 4
239000002245 particle Substances 0.000 description 4
210000003752 saphenous vein Anatomy 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000000556 agonist Substances 0.000 description 2
229940054051 antipsychotic indole derivative Drugs 0.000 description 2
239000003925 fat Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
ALHJUKAHBQYJEL-UHFFFAOYSA-N 1-[3-[2-(dimethylamino)ethyl]-1,2-dihydroindol-3-yl]-n-methylmethanesulfonamide Chemical compound C1=CC=C2C(CS(=O)(=O)NC)(CCN(C)C)CNC2=C1 ALHJUKAHBQYJEL-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
229940125684 antimigraine agent Drugs 0.000 description 1
239000002282 antimigraine agent Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000007705 chemical test Methods 0.000 description 1
230000001595 contractor effect Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
AMKVXSZCKVJAGH-UHFFFAOYSA-N naratriptan Chemical compound C12=CC(CCS(=O)(=O)NC)=CC=C2NC=C1C1CCN(C)CC1 AMKVXSZCKVJAGH-UHFFFAOYSA-N 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000012856 packing Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229940068984 polyvinyl alcohol Drugs 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000007892 solid unit dosage form Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
PORMUFZNYQJOEI-UHFFFAOYSA-N sumatriptan succinate Chemical compound OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 PORMUFZNYQJOEI-UHFFFAOYSA-N 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

IL10546893A 1992-05-07 1993-04-20 Pharmaceutical preparations containing agonists for TH5-1-like receptors for rectal administration IL105468A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB929209882A GB9209882D0 (en)	1992-05-07	1992-05-07	Compositions

Publications (2)

Publication Number	Publication Date
IL105468A0 IL105468A0 (en)	1993-08-18
IL105468A true IL105468A (en)	1998-09-24

Family

ID=10715158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL10546893A IL105468A (en)	1992-05-07	1993-04-20	Pharmaceutical preparations containing agonists for TH5-1-like receptors for rectal administration

Country Status (33)

Country	Link
US (1)	US5705506A (it)
EP (1)	EP0639072B1 (it)
JP (1)	JPH07506570A (it)
KR (1)	KR100253111B1 (it)
AT (1)	ATE163850T1 (it)
AU (1)	AU670083B2 (it)
BE (1)	BE1007024A5 (it)
BG (1)	BG62120B1 (it)
BR (1)	BR1100108A (it)
CA (1)	CA2135179C (it)
CH (1)	CH685920A5 (it)
CY (1)	CY2039B1 (it)
CZ (1)	CZ283512B6 (it)
DE (1)	DE69317418T2 (it)
ES (1)	ES2113533T3 (it)
FR (1)	FR2690847B1 (it)
GB (2)	GB9209882D0 (it)
GR (1)	GR3026584T3 (it)
HK (1)	HK95697A (it)
HU (2)	HU227338B1 (it)
IE (1)	IE75203B1 (it)
IL (1)	IL105468A (it)
IT (1)	IT1261471B (it)
NO (1)	NO306700B1 (it)
NZ (1)	NZ252132A (it)
OA (1)	OA10109A (it)
RO (1)	RO112993B1 (it)
RU (1)	RU2118527C1 (it)
SG (1)	SG46649A1 (it)
TW (1)	TW231970B (it)
UA (1)	UA37206C2 (it)
WO (1)	WO1993021916A1 (it)
ZA (1)	ZA933178B (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997044062A1 (en) *	1996-05-23	1997-11-27	Alcon Laboratories, Inc.	The use of 5-ht1b/1d agonists to treat ocular pain
US7189753B1 (en)	1997-11-06	2007-03-13	Cady Roger K	Preemptive prophylaxis of migraine
AU749623B2 (en) *	1998-03-26	2002-06-27	Astellas Pharma Inc.	Sustained release preparations
AU3731400A (en) *	1999-03-05	2000-09-21	Trustees Of University Technology Corporation, The	Methods and compositions useful in inhibiting apoptosis
AR056690A1 (es) *	2005-10-14	2007-10-17	Athersys Inc	Derivados de indol como inhibidores de indol como inhibidores del receptor 3 de histamina para el tartamiento de trastornos del sueno y cognitivos obesidad y otros trastornos de snc
US8653066B2 (en)	2006-10-09	2014-02-18	Charleston Laboratories, Inc.	Pharmaceutical compositions
EP2240022B1 (en)	2008-01-09	2016-12-28	Charleston Laboratories, Inc.	Bilayered tablets comprising oxycodone and promethazine
EP2451274B1 (en)	2009-07-08	2017-10-04	Charleston Laboratories, Inc.	Pharmaceutical compositions
CN103402514B (zh)	2010-10-15	2016-01-13	康特拉医药公司	用于治疗运动障碍的血清素受体激动剂组合物
MY169068A (en)	2012-04-18	2019-02-12	Contera Pharma Aps	Orally available pharmaceutical formulation suitable for improved management of movement disorders
US10179109B2 (en)	2016-03-04	2019-01-15	Charleston Laboratories, Inc.	Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
CN109689036B (zh)	2016-07-11	2026-06-19	康特拉医药股份有限公司	用于治疗早晨运动不能的脉冲药物输送系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZW19381A1 (en) *	1980-08-12	1983-03-09	Glaxo Group Ltd	Heterocyclic compounds
DK157995C (da) *	1980-08-12	1990-08-06	Glaxo Group Ltd	Analogifremgangsmaade til fremstilling af indolderivater
GB2082175B (en) *	1980-08-12	1984-05-02	Glaxo Group Ltd	Heterocyclic compounds
GR79215B (it) *	1982-06-07	1984-10-22	Glaxo Group Ltd
GB8332435D0 (en) *	1983-12-06	1984-01-11	Glaxo Group Ltd	Chemical compounds
GB2162522B (en) *	1984-08-01	1988-02-24	Glaxo Group Ltd	An indole derivative
GB8419575D0 (en) *	1984-08-01	1984-09-05	Glaxo Group Ltd	Chemical compounds
US4785016A (en) *	1984-12-04	1988-11-15	Glaxo Group Limited	Indole derivatives
GB8431426D0 (en) *	1984-12-13	1985-01-23	Glaxo Group Ltd	Chemical compounds
EP0225726B1 (en) *	1985-11-08	1991-04-17	Glaxo Group Limited	Indole derivatives
PH24976A (en) *	1987-08-13	1990-12-26	Glaxo Group Ltd	Indole derivatives
CZ288351B6 (en) *	1990-06-07	2001-05-16	Astrazeneca Ab	Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof

1992
- 1992-05-07 GB GB929209882A patent/GB9209882D0/en active Pending
1993
- 1993-04-20 IL IL10546893A patent/IL105468A/en not_active IP Right Cessation
- 1993-05-03 UA UA94115989A patent/UA37206C2/uk unknown
- 1993-05-03 DE DE69317418T patent/DE69317418T2/de not_active Expired - Lifetime
- 1993-05-03 JP JP5518928A patent/JPH07506570A/ja active Pending
- 1993-05-03 US US08/331,485 patent/US5705506A/en not_active Expired - Fee Related
- 1993-05-03 AU AU40640/93A patent/AU670083B2/en not_active Ceased
- 1993-05-03 AT AT93909884T patent/ATE163850T1/de active
- 1993-05-03 NZ NZ252132A patent/NZ252132A/en not_active IP Right Cessation
- 1993-05-03 RU RU94046069/14A patent/RU2118527C1/ru not_active IP Right Cessation
- 1993-05-03 CA CA002135179A patent/CA2135179C/en not_active Expired - Fee Related
- 1993-05-03 CZ CZ942723A patent/CZ283512B6/cs not_active IP Right Cessation
- 1993-05-03 ES ES93909884T patent/ES2113533T3/es not_active Expired - Lifetime
- 1993-05-03 WO PCT/EP1993/001077 patent/WO1993021916A1/en not_active Ceased
- 1993-05-03 HU HU9403188A patent/HU227338B1/hu unknown
- 1993-05-03 EP EP93909884A patent/EP0639072B1/en not_active Expired - Lifetime
- 1993-05-03 RO RO94-01790A patent/RO112993B1/ro unknown
- 1993-05-05 SG SG1996007136A patent/SG46649A1/en unknown
- 1993-05-05 GB GB9309209A patent/GB2266665B/en not_active Expired - Lifetime
- 1993-05-06 BE BE9300467A patent/BE1007024A5/fr not_active IP Right Cessation
- 1993-05-06 IE IE930339A patent/IE75203B1/en not_active IP Right Cessation
- 1993-05-06 CH CH139793A patent/CH685920A5/fr not_active IP Right Cessation
- 1993-05-06 ZA ZA933178A patent/ZA933178B/xx unknown
- 1993-05-06 FR FR9305432A patent/FR2690847B1/fr not_active Expired - Lifetime
- 1993-05-06 IT ITRM930286A patent/IT1261471B/it active IP Right Grant
- 1993-05-12 TW TW082103742A patent/TW231970B/zh active
1994
- 1994-11-04 OA OA60578A patent/OA10109A/en unknown
- 1994-11-04 NO NO944214A patent/NO306700B1/no not_active IP Right Cessation
- 1994-11-05 KR KR1019940703950A patent/KR100253111B1/ko not_active Expired - Fee Related
- 1994-11-07 BG BG99167A patent/BG62120B1/bg unknown
1995
- 1995-06-29 HU HU95P/P00531P patent/HU211638A9/hu unknown
1996
- 1996-12-24 BR BR1100108-9A patent/BR1100108A/pt active IP Right Grant
1997
- 1997-06-26 HK HK95697A patent/HK95697A/xx not_active IP Right Cessation
1998
- 1998-04-10 GR GR980400773T patent/GR3026584T3/el unknown
- 1998-04-30 CY CY9802039A patent/CY2039B1/xx unknown

Also Published As

Publication number	Publication date
HU211638A9 (en)	1995-12-28
NZ252132A (en)	1996-09-25
NO306700B1 (no)	1999-12-13
EP0639072B1 (en)	1998-03-11
GB2266665A (en)	1993-11-10
KR100253111B1 (en)	2000-07-01
ATE163850T1 (de)	1998-03-15
IE930339A1 (en)	1993-11-17
NO944214D0 (no)	1994-11-04
HK95697A (en)	1997-08-08
BE1007024A5 (fr)	1995-02-21
BG62120B1 (bg)	1999-03-31
FR2690847A1 (fr)	1993-11-12
OA10109A (en)	1996-12-18
BG99167A (bg)	1995-06-30
RO112993B1 (ro)	1998-03-30
RU2118527C1 (ru)	1998-09-10
ZA933178B (en)	1994-01-10
IE75203B1 (en)	1997-08-27
AU670083B2 (en)	1996-07-04
HUT71418A (en)	1995-11-28
BR1100108A (pt)	1999-12-07
IT1261471B (it)	1996-05-23
ES2113533T3 (es)	1998-05-01
FR2690847B1 (fr)	1995-06-09
ITRM930286A0 (it)	1993-05-06
UA37206C2 (uk)	2001-05-15
JPH07506570A (ja)	1995-07-20
EP0639072A1 (en)	1995-02-22
CY2039B1 (en)	1998-04-30
GR3026584T3 (en)	1998-07-31
US5705506A (en)	1998-01-06
GB2266665B (en)	1996-05-22
AU4064093A (en)	1993-11-29
GB9309209D0 (en)	1993-06-16
DE69317418D1 (de)	1998-04-16
WO1993021916A1 (en)	1993-11-11
TW231970B (it)	1994-10-11
CA2135179A1 (en)	1993-11-11
IL105468A0 (en)	1993-08-18
SG46649A1 (en)	1998-02-20
ITRM930286A1 (it)	1994-11-06
CH685920A5 (fr)	1995-11-15
GB9209882D0 (en)	1992-06-24
CZ283512B6 (cs)	1998-04-15
NO944214L (no)	1994-11-07
CA2135179C (en)	2000-12-05
DE69317418T2 (de)	1998-07-30
HU227338B1 (en)	2011-04-28
CZ272394A3 (en)	1995-10-18

Legal Events

Date	Code	Title
1999-01-26	FF	Patent granted
1999-07-14	KB	Patent renewed
1999-10-28	KB	Patent renewed
2003-06-24	KB	Patent renewed
2007-07-24	KB	Patent renewed
2011-12-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
CN100448439C (zh)	2009-01-07	用于头痛、偏头痛、恶心和呕吐的药物组合物
US5705506A (en)	1998-01-06	Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration
US5629336A (en)	1997-05-13	Use of glycine/NMDA receptor ligands for the treatment of drug dependence and withdrawal
AP544A (en)	1996-10-11	Compositions for rectal administration
WO2002015899A1 (en)	2002-02-28	Combination therapy for the treatment of migraine
US5854248A (en)	1998-12-29	Nefazodone: use in migraine prophylaxis
EP0671908B1 (en)	1998-05-06	Pharmaceutical compositions comprising 5-ht 1? receptor agonists and absorption enhancers
AU3810100A (en)	2000-10-04	Stable pharmaceutical application form for paroxetin anhydrate